Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c

American Heart Journal

Volumn 168, Issue 4, 2014, Pages 457-465.e2

  Arnold, Suzanne V ^a,b   McGuire, Darren K ^c   Spertus, John A ^a,b   Li, Yan ^a   Yue, Patrick ^d   Ben Yehuda, Ori ^e   Belardinelli, Luiz ^d   Jones, Philip G ^a   Olmsted, Ann ^d   Chaitman, Bernard R ^f   Kosiborod, Mikhail ^a,b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d GILEAD SCIENCES   (United States)

^e CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^f SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LONG ACTING DRUG; NITRIC ACID DERIVATIVE; PLACEBO; RANOLAZINE; ACETANILIDE DERIVATIVE; ENZYME INHIBITOR; GLYCOSYLATED HEMOGLOBIN; PIPERAZINE DERIVATIVE;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; GLYCEMIC CONTROL; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; POST HOC ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEATTLE ANGINA QUESTIONNAIRE; SODIUM CURRENT; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; ANGINA, STABLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; METABOLISM; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ACETANILIDES; ANGINA, STABLE; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922243592     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.06.020     Document Type: Article

References (28)

1. B.R. Chaitman, S.L. Skettino, and J.O. Parker Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina J Am Coll Cardiol 43 8 2004 1375 1382
2. M.F. Rousseau, H. Pouleur, and G. Cocco Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris Am J Cardiol 95 3 2005 311 316
3. B.R. Chaitman, C.J. Pepine, and J.O. Parker Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 291 3 2004 309 316
4. P.H. Stone, N.A. Gratsiansky, and A. Blokhin Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial J Am Coll Cardiol 48 3 2006 566 575
5. S.V. Arnold, D.A. Morrow, and K. Wang Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial Circ Cardiovasc Qual Outcomes 1 2 2008 107 115
6. M. Kosiborod, S.V. Arnold, and J.A. Spertus Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) J Am Coll Cardiol 61 20 2013 2038 2045
7. S.V. Arnold, M. Kosiborod, and D.K. McGuire Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina JAMA Intern Med 2014 Jun 2 10.1001/jamainternmed.2014.2120 [Epub ahead of print]
8. B.R. Chaitman Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions Circulation 113 20 2006 2462 2472
9. L. Belardinelli, J.C. Shryock, and H. Fraser Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine Heart 92 Suppl. 4 2006 iv6 iv14
10. Z. Lu, Y.P. Jiang, and C.Y. Wu Increased persistent sodium current Due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart Diabetes 62 12 2013 4257 4265
11. C. Antzelevitch, L. Belardinelli, and A.C. Zygmunt Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 110 8 2004 904 910
12. J.A. Spertus, J.A. Winder, and T.A. Dewhurst Monitoring the quality of life in patients with coronary artery disease Am J Cardiol 74 12 1994 1240 1244
13. J.A. Spertus, J.A. Winder, and T.A. Dewhurst Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease J Am Coll Cardiol 25 2 1995 333 341
14. G.A. Rose, and H. Blackburn Cardiovascular survey methods Monogr Ser World Health Organ 56 1968 1 188
15. J.E. Ware Jr., and C.D. Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 30 6 1992 473 483
16. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 6 2012 1364 1379
17. D.A. Morrow, B.M. Scirica, and B.R. Chaitman Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial Circulation 119 15 2009 2032 2039
18. 1c in patients with chronic angina and diabetes Eur Heart J 27 1 2006 42 48
19. M. Yang, R. Chu, and L. Belardinelli Inhibition of glucagon secretion in rat pancreatic islets via Na + channels: mechanism of anti-diabetic effect of ranolazine Diabetes 62 Suppl. 1 2013 A234
20. K. Kahlig, M. Yang, and X. Cheng The mechanism of the anti-diabetic effect of ranolazine: inhibition of glucagon secretion in rat pancreatic islets via Na + channel blockade Diabetes 62 Suppl. 1 2013 A272
21. A. Dhalla, M. Yang, and R. Chu Ranolazine inhibits glucogon secretion from human pancreatic islets via blockade of the Nav1.3 channels in alpha-cells Diabetes 62 Suppl. 1 2013 A227
22. Y. Ning, M. Van Petten, and J. Jiang Na channel blockers exert anti-diabetic effects via lowering glucagon levels in ZDF diabetic rats Diabetes 62 Suppl. 1 2013 A280
23. Y. Ning, J. Jiang, and M. Van Petten Ranolazine suppresses exaggerated postprandial glucagon response in STZ-induced diabetic rats Diabetes 62 Suppl. 1 2013 A235
24. S. Nishio, Y. Teshima, and N. Takahashi Activation of CaMKII as a key regulator of reactive oxygen species production in diabetic rat heart J Mol Cell Cardiol 52 5 2012 1103 1111
25. O.M. Koval, J.S. Snyder, and R.M. Wolf Ca2+/calmodulin-dependent protein kinase II-based regulation of voltage-gated Na + channel in cardiac disease Circulation 126 17 2012 2084 2094
26. F. Paneni, J.A. Beckman, and M.A. Creager Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I Eur Heart J 34 31 2013 2436 2443
27. P. Deedwania, M. Kosiborod, and E. Barrett Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation 117 12 2008 1610 1619
28. Department of Health and Human Services Centers for disease control and prevention. Age-adjusted percentage of civilian, noninstitutionalized population with diagnosed diabetes, by race and sex, United States, 1980-2011 http://www.cdc.gov/diabetes/statistics/prev/national/figraceethsex.htm [Accessed October 22, 2013. In]